News 09 Apr. 2024
Curtis Announces New Partners and Counsels Across Offices in Spring 2024
more
News 25 Jan. 2024
Counsel Mohannad A. El Murtadi Suleiman Addresses “Africanization” of International Investment Law
Event 18 Aug. 2023
Partner Borzu Sabahi Speaks at FDI Moot Shenzhen
News 25 Jul. 2023
Partner Eric Gilioli Ranked in Top 10 Influential Energy & Natural Resources Lawyers in Kazakhstan in Business Today
Client Alert 28 Dec. 2023
U.S. to Impose Secondary Sanctions on Non-U.S. Banks For Financing Russia’s Defense Industry
News 28 Aug. 2024
Curtis Recognized for Excellence in Arbitration in Chambers Latin America Guide 2025
Event 22 Aug. 2023
Partner Dr. Claudia Frutos-Peterson to Speak at Arbitration and ADR Commission of the ICC Mexico
News 15 Aug. 2023
Legal Reader Publishes Article on Dr. Majed Alotaibi’s Arrival as Senior Counsel in Curtis’ Riyadh Office
News 31 Jul. 2023
Curtis Welcomes Senior Saudi Advisor, Dr. Majed Alotaibi, to its Riyadh Office
News 24 Aug. 2023
Curtis Attorneys Quoted in CoinDesk on FTX Founder Sam Bankman-Fried’s Strategy Ahead of His Criminal Trial
Client Alert 10 Jul. 2024
EU Adopts New Restrictive Measures Against Belarus
Client Alert 26 Jun. 2024
The EU Adopts its 14th Sanctions Package Against Russia
news
Curtis Partner and Islamic Finance Expert, Michael McMillen appointed Consulting Professor at the Prestigious Prince Sultan...
Curtis Lawyers Featured in Bloomberg Law Article, ‘Uber’s Massive EU Fine Is a Warning Should New Privacy Deal Fall.’
News 12 Oct. 2012
New York, October 11, 2012 — Curtis, Mallet-Prevost, Colt & Mosle LLP represented Bionomics Limited in the Australian biotechnology company's acquisition of San Diego-based Eclipse Therapeutics Inc.
The transaction was structured as a stock-for-stock reverse. Additional cash consideration may be payable post-closing upon the achievement of certain milestones.
Bionomics, as a result of the deal, will gain an important strategic base in the United States, the world's largest pharmaceutical market, with the acquisition. The addition of Eclipse will expand Bionomics' oncology pipeline and establish the company as a global leader at the forefront of cancer stem cell therapeutics.
Bionomics, based in Adelaide, is a leading international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, Alzheimer's disease, epilepsy and multiple sclerosis.
Eclipse Therapeutics is a private biotech company that was spun off from Biogen Idec Inc. Eclipse develops drug compounds that target cancer stem cells, the root cause of many cancers.
The Curtis team of attorneys was led by partner Lawrence Goodman and associates Douglas Glazer and Joshua Holt from the Corporate M&A group, partner Alan Berlin and counsel Kuang-Chu Chiang from the Tax group, and counsel Eric Stenshoel from the Intellectual Property practice.
The Curtis Mergers & Acquisition practice group focuses primarily on middle market M&A and private equity transactions across a broad range of industries. Curtis advises both private and public entities and financial sponsors in a broad range of transactional matters, counseling buyers, sellers and targets in connection with mergers, acquisitions, joint ventures, leveraged buy-outs, strategic alliances and other related transactions. The Curtis M&A group has extensive experience in complex cross-border transactions and foreign investments in the United States, Europe, Latin America, the Middle East and Asia.
Curtis, Mallet-Prevost, Colt & Mosle LLP is a leading international law firm providing a broad range of services to clients around the world. Curtis has 16 offices in the United States, Latin America, Europe, Central Asia, and the Middle East. The firm's international orientation has been a hallmark of its practice for nearly two centuries. For more information about Curtis, please visit www.curtis.com or follow Curtis on Twitter (twitter.com/curtislawfirm) and Facebook.com/Curtis.Careers).
Mergers and Acquisitions
Private Equity
Douglas Ian Glazer
Partner
Lawrence Goodman
Eric Stenshoel
Counsel
We use cookies on our website to enhance your browsing experience, match your interests and assess our website performance. We do not share information with any third-party for marketing purposes. Please view our privacy policy to learn more about the use of cookies on our website. By continuing to browse our website, you consent to our use of cookies.